Lacosamide G.L. Pharma Gmbh

Lacosamide, the active ingredient in Lacosamide G.L. Pharma Gmbh, is an anticonvulsant presented as an oral tablet for oral use. It reduces neuronal excitability and is indicated for the treatment of partial‑onset seizures in patients with epilepsy. The medication works by enhancing the slow inactivation of voltage‑gated sodium channels, thereby stabilizing neuronal membranes.

GNH USA supplies Lacosamide G.L. Pharma Gmbh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and compliance with global regulatory standards.

Lacosamide is an anticonvulsant used in the management of focal seizure disorders. - Partial-onset seizures: Reduces seizure frequency in patients with epilepsy. - Focal seizures with secondary generalization: Provides adjunctive control when seizures spread from a focal origin. - Adjunctive therapy for focal epilepsy: Used in combination with other antiepileptic drugs to improve overall seizure management.

Lacosamide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache

Serious or Rare Side Effects: - PR interval prolongation (cardiac conduction abnormality) - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior

Before initiating therapy, consider the following precautions. - Assess cardiac function: monitor ECG for PR interval prolongation before and during therapy. - Review renal function: adjust dosing in patients with severe renal impairment. - Avoid abrupt discontinuation: taper the dose to prevent seizure worsening. - Caution in hepatic disease: monitor liver enzymes regularly. - Pregnancy and breastfeeding: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lacosamide can interact with several medications, influencing its efficacy or safety.

Major Interactions (Avoid): - Co‑administration with other sodium‑channel blockers (e.g., carbamazepine) may increase risk of cardiac conduction effects. - Use with drugs that significantly prolong PR interval (e.g., verapamil) can exacerbate cardiac abnormalities.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inducers (e.g., rifampin) may reduce lacosamide plasma levels. - CYP3A4 inhibitors (e.g., ketoconazole) may increase lacosamide concentrations. - Concurrent antiepileptic drugs may require dose adjustments to maintain seizure control.